|
¼ò½é
¸Î±¦(Milk Thistle£¬Ë׳ÆÄ̼»)ÊÇÅ·ÃÀ×î³£Óõı£»¤¸Î¹¦Äܽ¡¿µµÄÌìÈ»²ÝÒ©¡£
ÁÙ´²Ñо¿±íÃ÷¸Î±¦¾ßÓп¹Ñõ»¯×÷Óá£ÄÜÓÐЧµØ±£»¤¸Îϸ°ûÃâÊܾƾ«Öж¾»òÓж¾»¯Ñ§ÎïÖÊÒýÆðµÄËðÉË£¬ÒÔ¼°¸ÄÉÆÂýÐԸβ¡»ò¸ÎÓ²»¯µÄÖ¢×´£¬¶øÇÒûÓи±×÷Óᣆ
ÒÔMilk ThistleΪÖ÷³É·Ö, Õë¶Ô»ªÈ˵IJúÆ·²»ÉÙ, °üÀ¨ÃÀ¹ú°®µÂ»ªµÄ¡°ÃÀ¹úÌØÐ§Ñø¸ÎËØ¡±, µÂ¹úÂí²©Ê¿´óÒ©³§µÄÀû¼Ó¡µÈ¡£
|
|
²Î¿¼ÎÄÏ×
1. Bokemeyer C,
Fels LM, Dunn T, Voigt W, Gaedeke J, Schmoll HJ,
Stolte H, Lentzen H. Silibinin protects against
cisplatin-induced nephrotoxicity without
compromising cisplatin or ifosfamide anti-tumour
activity. Br J Cancer. 1996 Dec;74(12):2036-41.
2.
http://www.nci.nih.gov/cancertopics/pdq/cam/milkthistle/HealthProfessional/page9/print
3. Ferenci P, Dragosics B, Dittrich H, Frank H,
Benda L, Lochs H, Meryn S, Base W, Schneider B.
Randomized controlled trial of silymarin
treatment in patients with cirrhosis of the
liver. J Hepatol. 1989 Jul;9(1):105-13.
by X. Li, Ph. D. (credential)
±¾ÄÚÈÝÊÜ֪ʶ²úȨ·¨Âɱ£»¤£¬ÈçÓÐÇÖº¦½«×·Ëß·¨ÂÉÔðÈΡ£
|